Roche announces CHMP recommendation for EU approval of Venclyxto plus Gazyvaro for people with untreated chronic lymphocytic leukaemia
Basel, 31 January 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto® (venetoclax) in combination with Gazyvaro® (obinutuzumab) for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).“Despite advances in treating chronic lymphocytic leukaemia, many patients cannot tolerate the side effects of chemotherapy-containing regimens,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product ...
Source: Roche Investor Update - January 31, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the European Commission has granted conditional marketing authorisation for Polivy ® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - January 21, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the European Commission has granted conditional marketing authorisation for Polivy ® (polatuzumab vedotin), in combination with bendamustine plus MabThera® (rituximab) (BR), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - January 21, 2020 Category: Pharmaceuticals Source Type: news

Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCL
Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Diego Villa, MD, FRCPC Source Type: news

Truxima (Rituximab-abbs Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 2, 2020 Category: Drugs & Pharmacology Source Type: news

Switching From Rituximab to Biosimilar CT-P10 in RA Switching From Rituximab to Biosimilar CT-P10 in RA
CT-P10, a biosimilar of reference rituximab, may be a safe and effective treatment option for patients with rheumatoid arthritis.Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 20, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Amgen and Allergan submit Biologics License Application for ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA. (Source: World Pharma News)
Source: World Pharma News - December 19, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

John M. Pagel, MD, PhD, on Polatuzumab Vedotin
The Swedish Cancer Center expert discussed the addition of polatuzumab vedotin to a bendamustine-rituximab regimen at the ASH Annual Meeting& Exposition. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2019 Category: Cancer & Oncology Authors: John M. Pagel, MD, PhD Source Type: news

IMBRUVICA ® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia
· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were m aintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA® · IMBRUVICA® plus ven e...
Source: Johnson and Johnson - December 9, 2019 Category: Pharmaceuticals Source Type: news

Ibrutinib/Rituximab Combo Induced Superior PFS in Older Patients with CLL
The combination of ibrutinib and rituximab demonstrated superior progression-free survival in older patients with previously untreated chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Wayne Kuznar Source Type: news

Lenalidomide/Rituximab Combo Improves PFS in Subgroup of Patients with NHL
Treatment with lenalidomide and rituximab improved progression-free survival, compared with placebo in patients ≥70 years old with indolent non-Hodgkin lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 9, 2019 Category: Cancer & Oncology Authors: Gina Columbus Source Type: news

CHMP recommends conditional EU approval of Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy ® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends conditional EU approval of Roche ’s Polivy for people with previously treated aggressive lymphoma
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Polivy ® (polatuzumab vedotin) in combination with bendamustine plus MabThera® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant. (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2019 Category: Pharmaceuticals Source Type: news

Penn uncovers dose of medication more likely to put patients with pemphigus into remission
(University of Pennsylvania School of Medicine) Researchers from Penn compare a lymphoma-dose regimen of rituximab to a rheumatoid arthritis regimen for the treatment of pemphigus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2019 Category: International Medicine & Public Health Source Type: news

Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 8, 2019 Category: Pharmaceuticals Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Media News)
Source: Roche Media News - October 14, 2019 Category: Pharmaceuticals Source Type: news

Phase III PEMPHIX study shows Roche ’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
Roche today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Investor Update)
Source: Roche Investor Update - October 14, 2019 Category: Pharmaceuticals Source Type: news

Different Infection Risks for MS Treatments Different Infection Risks for MS Treatments
New study results suggest rituximab has a higher risk of serious infections than fingolimod or natalizumab, but a lower risk of herpetic infections.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 11, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

Subcutaneous Rituximab Maintained Efficacy, Was Safe in DLBCL, FL
Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues. (Source: CancerNetwork)
Source: CancerNetwork - October 9, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Rituxan Approved for Pediatric Patients With Rare Vasculitis Diseases
Title: Rituxan Approved for Pediatric Patients With Rare Vasculitis DiseasesCategory: Health NewsCreated: 10/1/2019 12:00:00 AMLast Editorial Review: 10/2/2019 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - October 2, 2019 Category: Rheumatology Source Type: news

Rituxan Approved for Pediatric Patients With Rare Vasculitis Diseases
TUESDAY, Oct. 1, 2019 -- Rituxan (rituximab) injection was granted the first approval for a drug to treat granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in combination with glucocorticoids in children 2 years and older,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 1, 2019 Category: General Medicine Source Type: news

FDA OKs First Treatment for Rare Types of Vasculitis in Kids FDA OKs First Treatment for Rare Types of Vasculitis in Kids
The FDA has approved rituximab injection for granulomatosis with polyangiitis and microscopic polyangiitis in children aged 2 years or older.FDA Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 30, 2019 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news

FDA approves Roche ’s Rituxan (rituximab) in children with two rare blood vessel disorders
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older. (Source: Roche Media News)
Source: Roche Media News - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Rituxan (rituximab) in children with two rare blood vessel disorders
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan ® (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) in paediatric patients 2 years of age and older. (Source: Roche Investor Update)
Source: Roche Investor Update - September 30, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Rituxan (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) in Children
South San Francisco, CA -- September 27, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab), in combination with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2019 Category: Drugs & Pharmacology Source Type: news

Abatacept, Rituximab, Tocilizumab and TNFi Biologics in RA Abatacept, Rituximab, Tocilizumab and TNFi Biologics in RA
How do these drugs for the treatment of rheumatoid arthritis compare in terms of efficacy and outcomes?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Can m7 FLIPI Score Predict Prognosis in Follicular Lymphoma?
A new study evaluated whether  the m7-FLIPI score in patients with follicular lymphoma treated with rituximab without chemotherapy can indicate prognosis. (Source: CancerNetwork)
Source: CancerNetwork - September 13, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 7, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 7, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

Ibrutinib Combo in Chronic Lymphocytic Leukemia is Superior, but Costly
While  ibrutinib plus rituximab may improve progression-free survival in chronic lymphocytic leukemia, it is a costly option for some patients. (Source: CancerNetwork)
Source: CancerNetwork - September 3, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan ® (rituximab)
Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798, a biosimilar candidate to Rituxan® (rituximab), compared to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. (Source: World Pharma News)
Source: World Pharma News - August 22, 2019 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news

Nanocapsule reaches cancer that has spread to central nervous system in mice
FINDINGSCancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in order to reach and treat cancer that has spread to the central nervous system.In research conducted in mice, a single dose of cancer drugs in a nanoscale capsule developed by the scientists eliminated all B-cell lymphoma that had metastasized to the animals ’ central nervous system.BACKGROUNDAbout 15% to 40% of all cancers spread to the nervous system, but there are few treatment options and they only work in a small ...
Source: UCLA Newsroom: Health Sciences - August 14, 2019 Category: Universities & Medical Training Source Type: news

Examining MRD-Driven Consolidation with Rituximab in Early Stage Follicular Lymphoma
Patients with follicular lymphoma who were minimal residual disease-positive after undergoing involved field radiation therapy were given  rituximab to see how it affected progression-free survival.  (Source: CancerNetwork)
Source: CancerNetwork - August 12, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Promising New Combo Found For DLBCL
A combination of ibrutinib, lenalidomide, and rituximab was tested on patients with  relapsed or refractory diffuse large B-cell lymphoma, particularly those with non-GCB subtype. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Drug Duo May Be a Weapon Against a Common Leukemia
The phase 3 trial of more than 500 U.S. patients with chronic lymphocytic leukemia (CLL) found that a combination of rituximab and ibrutinib extended patient survival. (Source: WebMD Health)
Source: WebMD Health - August 1, 2019 Category: Consumer Health News Source Type: news

Ibrutinib - Rituximab Beats Chemoimmunotherapy for CLL
Progression - free, overall survival improved in the ibrutinib - rituximab group at three years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - August 1, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Ibrutinib-Rituximab Beats Chemoimmunotherapy for CLL
THURSDAY, Aug. 1, 2019 -- For patients with previously untreated chronic lymphocytic leukemia (CLL), ibrutinib-rituximab is more efficacious than chemoimmunotherapy, according to a study published in the Aug. 1 issue of the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 1, 2019 Category: Pharmaceuticals Source Type: news

Ruxience (Rituximab-pvvr Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 1, 2019 Category: Drugs & Pharmacology Source Type: news

Ruxience (Rituximab-pvvr Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 31, 2019 Category: Drugs & Pharmacology Source Type: news

ASCT May Offer Alternative for Tx of High - Risk Follicular Lymphoma
Autologous stem cell transplantation explored for high - risk, early therapy failure FL prior to rituximab use (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 25, 2019 Category: Cancer & Oncology Tags: Oncology, Institutional, Source Type: news

ASCT May Offer Alternative for Tx of High-Risk Follicular Lymphoma
THURSDAY, July 25, 2019 -- Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, according to a study published online July... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 25, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Ruxience (rituximab-pvvr), a Biosimilar to Rituxan
July 23, 2019 - Pfizer Inc. today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab),1 for the treatment of adult patients with non-Hodgkin’s... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 23, 2019 Category: Drugs & Pharmacology Source Type: news

Rituximab Noninferior to Cyclosporine in Membranous Nephropathy
WEDNESDAY, July 17, 2019 -- In patients with membranous nephropathy at high risk for progressive disease, rituximab is noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and is superior in maintaining... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 17, 2019 Category: Pharmaceuticals Source Type: news

Rituximab +/- Idelalisib Followed by Idelalisib in CLL Rituximab +/- Idelalisib Followed by Idelalisib in CLL
For patients with relapsed CLL, does the addition of the small molecule inhibitor idelalisib to rituximab improve PFS and OS?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

MENTOR: Rituximab Is a Winner in Membranous Nephropathy MENTOR: Rituximab Is a Winner in Membranous Nephropathy
The anti-CD20 antibody is clearly superior to cyclosporine in inducing, maintaining proteinuria remission in patients with membranous nephropathy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 3, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news

Novel Drug Targets Lymphoma Cells'' Don't Eat Me' Signal Novel Drug Targets Lymphoma Cells'' Don't Eat Me' Signal
The first-in-class agent Hu5F9 is a macrophage immune checkpoint inhibitor and, when added onto rituximab, shows potentially long-lasting efficacy in patients with relapsed and refractory lymphoma.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 19, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA grants Roche's Polivy accelerated approval for people with previously treated aggressive lymphoma
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. (Source: World Pharma News)
Source: World Pharma News - June 13, 2019 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Phase III PEMPHIX study showed that Roche ’s Mabthera/Rituxan (rituximab) is superior to standard of care in achieving sustained remission in patients with pemphigus vulgaris
Roche today announced positive topline results from the Roche-sponsored phase III PEMPHIX study, evaluating the efficacy and safety of MabThera ®/Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). (Source: Roche Investor Update)
Source: Roche Investor Update - June 13, 2019 Category: Pharmaceuticals Source Type: news